| HOME >> MEDICINE >> TECHNOLOGY |
2010–2016 ($ THOUSANDS) 124
GLOBAL MAMMOGRAPHY EQUIPMENT MARKET 125
BREAST BIOPSY MARKET 126
MOLECULAR DIAGNOSTICS 127
COMPANION DIAGNOSTICS 127
PREDICTIVE TECHNOLOGY AND BREST CANCER MARKET TRENDS 127
TABLE 89 PREDICTIVE TECHNOLOGY 128
RELEVANT TESTS FOR BREAST CANCER PROGNOSIS 128
HER2 128
GENE EXPRESSION PROFILING TESTS 128
IHC4 TEST 129
TABLE 90 BREAST CANCER DIAGNOSTIC TEST COSTS 130
TABLE 91 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC
TECHNOLOGIES, THROUGH 2016 ($ MILLIONS) 131
FIGURE 14 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC
TECHNOLOGIES, 2010–2016 ($ MILLIONS) 131
IHC AND FISH-BASED TESTS AND MARKET 131
TABLE 92 IHC AND FISH-BASED BREAST CANCER TESTING SALES, THROUGH 2016 ($
MILLIONS) 132
FIGURE 15 IHC AND FISH-BASED BREAST CANCER TESTING SALES, 2010–2012 ($ MILLIONS) 132
TISSUE-BASED IMMUNOHISTOCHEMISTRY MARKET 133
TABLE 93 FDA-APPROVED COMMERCIAL KITS 133
HERCEP TEST KITS 134
TABLE 94 FDA-APPROVED FISH ANALYSIS TESTS 135
KEY COMPANIES 136
ROCHE 136
TABLE 95 ROCHE SALES BY DIVISION, 2010 ($ MILLIONS) 137
TABLE 96 ROCHE COMPANION DIAGNOSTICS CURRENTLY ON THE MARKET OR IN LATE
DEVELOPMENT FOR BREAST CANCER 137
DAKO 138
GENOMIC ASSAYS 138
TABLE 97 GENOMIC MARKET LEADERS 138
TABLE 98 GENOMIC TESTING MARKET FOR BREAST CANCER, THROUGH 2016 ($ MILLIONS) 139
FIGURE 16 GENOMIC TESTING MARKET FOR BREAST CANCER, 2010–2016 ($ MILLIONS) 139
GENOMIC HEALTH BUSINESS PROGRESS 140
TABLE 99 ONCOTYPE DX SALES, THROUGH 2016 ($ MILLIONS) 140
MAMMAPRINT ASSAY 140
QUANTITATIVE FLUORESCENCE-BASED TESTS 141
TABLE 100 QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST
CANCER, THROUGH 2016 ($
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |